G&A at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s G&A?
- Recursion Pharmaceuticals, Inc. (RXRX) reported G&A of $34.59M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s G&A changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s G&A decreased by 36.7% year-over-year, from $54.65M to $34.59M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s G&A?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s G&A has grown at a 32.3% compound annual growth rate (CAGR), from $57.68M to $176.59M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.